Clinical Cancer Research

Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

In this article (Clin Cancer Res 2016;22:1095–102), which was published in the March 1, 2016, issue of *Clinical Cancer Research* (1), the corresponding author informed us of a labeling error in Fig. 1D in the published article. This figure depicts the relationship between pMAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points. The figure legend and associated text refer to the data as being from "cycle 1 day 1." However, the current plot is actually pharmacokinetic/pharmacodynamic data from "cycle 1 day 14."

On page 1098, the legend for Fig. 1D should read as follows:

> D, the relationship between pMAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points following the cycle 1 day 14. Error bars represent SD.

On page 1100, the paragraph under the "Pharmacodynamics" heading in the Results section should read as follows:

> The primary pharmacodynamic biomarker in this study was p-MAPKAP-K2. Figure 1D illustrates the relationship between p-MAPKAP-K2 percent inhibition from baseline and ralimetinib plasma concentration at matching time points following the cycle 1 day 14 dose. In general, there was a reciprocal relationship between ralimetinib plasma concentration and pMAPKAPK-2 inhibition. At the dose of 300 mg in Part C and in Part D, the average pMAPKAPK-2 inhibition reached above 50% on day 1.

The conclusions put forth in this article remain unchanged. The authors regret this error.

Reference

1. Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, et al. A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 Dimesylate), in patients with advanced cancer. Clin Cancer Res 2016;22:1095–102.

Published online May 13, 2016.
doi: 10.1158/1078-0432.CCR-16-0645

Clinical Cancer Research

Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Clin Cancer Res 2016;22:2596.